Enrolling by invitationNot applicableNCT05368038
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Studying Acid sphingomyelinase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Albert Einstein College of Medicine
- Principal Investigator
- Melissa Wasserstein, MDAlbert Einstein College of Medicine
- Intervention
- Confirmatory Testing(diagnostic_test)
- Enrollment
- 100000 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2021 – 2029
Study locations (9)
- Maimonides Medical Center, Brooklyn, New York, United States
- NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States
- North Shore University Hospital, Manhasset, New York, United States
- NYU Langone Health - Tisch Hospital, New York, New York, United States
- Mount Sinai West, New York, New York, United States
- Mount Sinai Hospital, New York, New York, United States
- Long Island Jewish Medical Center, Queens, New York, United States
- Jack D. Weiler Hospital, The Bronx, New York, United States
- ScreenPlus Coordinating Core, Children's Hospital at Montefiore, The Bronx, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05368038 on ClinicalTrials.govOther trials for Acid sphingomyelinase deficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07274826Diagnostic Creteria of Acid Sphingomyelinase Deficiency (ASMD)Sohag University
- RECRUITINGNCT06192576A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)Sanofi